Latest news with #BridgeBioPharma
Yahoo
4 days ago
- Business
- Yahoo
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Is Expected To Breakeven In The Near Future
Explore BridgeBio Pharma's Fair Values from the Community and select yours BridgeBio Pharma, Inc. () is possibly approaching a major achievement in its business, so we would like to shine some light on the company. BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The US$9.8b market-cap company posted a loss in its most recent financial year of US$536m and a latest trailing-twelve-month loss of US$776m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is BridgeBio Pharma's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Consensus from 20 of the American Biotechs analysts is that BridgeBio Pharma is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$2.1m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 69% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. Given this is a high-level overview, we won't go into details of BridgeBio Pharma's upcoming projects, though, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. See our latest analysis for BridgeBio Pharma One thing we would like to bring into light with BridgeBio Pharma is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning. Next Steps: This article is not intended to be a comprehensive analysis on BridgeBio Pharma, so if you are interested in understanding the company at a deeper level, take a look at BridgeBio Pharma's company page on Simply Wall St. We've also compiled a list of essential factors you should further examine: Valuation: What is BridgeBio Pharma worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether BridgeBio Pharma is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BridgeBio Pharma's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Business
- Yahoo
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ...
Total Revenue: $110.6 million in Q2 2025, up from $2.2 million in the same period last year. Attruby Net Product Revenue: $71.5 million in U.S. net sales, representing 100% growth over Q1 2025. Royalty Revenue: $1.6 million from ex-U.S. net sales in Europe and Japan. License and Services Revenue: Increased by $35.3 million, including a $30 million regulatory milestone. Operating Costs and Expenses: $244.8 million in Q2 2025, up from $177.7 million in the same period last year. SG&A Expenses: Increased by $69.6 million. R&D Expenses: Declined by $3.5 million. Stock-Based Compensation Expense: $37.7 million, up from $21.5 million in Q2 2024. Cash Position: $756.9 million in cash, cash equivalents, and marketable securities. Attruby Prescriptions: 3,751 unique patient prescriptions and 1,074 unique prescribers. Weekly Script Growth: Over 30% growth in weekly scripts. New Patient Adds: Around 120 patients per week. Warning! GuruFocus has detected 8 Warning Signs with BBIO. Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BridgeBio Pharma Inc (NASDAQ:BBIO) reported strong growth in the launch of Attruby, with 100% revenue growth in Q2, reaching $78 million in global sales. The company has seen a significant increase in unique patient prescriptions for Attruby, with over 3,751 prescriptions and 1,074 unique prescribers. Attruby has demonstrated remarkable efficacy, with a 59% hazard reduction in time to first event in the variant population and a 43% reduction in risk of cardiac arrhythmia-related hospitalizations. BridgeBio Pharma Inc (NASDAQ:BBIO) has a strong cash position of $756.9 million, providing financial flexibility for future growth and development. The company is poised to become a diversified biopharma with up to three novel best or first-in-class assets in high unmet need areas, each representing billion-plus dollar opportunities. Negative Points Operating costs and expenses increased by $67.1 million compared to the same period last year, driven by a $69.6 million increase in SG&A expenses. The company faces competition in the ATTR cardiomyopathy market, particularly from Pfizer and Alnylam, which could impact market share. There is pressure on the switch category from competitors, particularly from knockdown agents, which could affect Attruby's growth. The market for some of BridgeBio Pharma Inc (NASDAQ:BBIO)'s pipeline products, such as ADH1, is poorly characterized and underdiagnosed, which could pose challenges in market penetration. The company is investing heavily in late-stage clinical programs, which could strain financial resources if expected outcomes are not achieved. Q & A Highlights Q: Can you break down the factors driving the increase in patient adds for Attruby, and how do you envision this trend changing in the upcoming quarters? A: Matthew Outten, Chief Commercial Officer: We're seeing strength in treatment-naive starts and continued switch activity. The market is expanding due to increased screening and awareness. Unique patient starts and prescriber counts are both increasing, making BridgeBio the partner of choice for healthcare professionals. The Attruby profile resonates with both patients and doctors, offering benefits as soon as 3 months and a 50% reduction in hospitalization rates. Neil Kumar, CEO: It's hard to tell the exact NBRx share, but it's estimated to be in the 18% to 20% range and growing. Better access and increasing scientific share of voice are driving commercial momentum. Q: How did the trends for the 28-day free trial, patient assistance programs, and gross to net evolve in the second quarter compared to the first quarter? A: Neil Kumar, CEO: We saw normalization in all three areas. The variant data showing the highest risk reduction in the V122I population and the broad variant population is crucial for serving underpenetrated populations with ATTR cardiomyopathy. These programs are important for reaching communities that have been historically underserved. We believe that our pricing and access programs will benefit us in the long term. Q: Can you discuss the community versus academic market share for Attruby and the potential market share for infigratinib in hypochondroplasia? A: Matthew Outten, Chief Commercial Officer: The overall data package combined with unmet need is driving growth. Patients are looking for effective treatments, and Attruby meets those needs. The market is growing as more people are diagnosed. Justin To, CEO, Skeletal Dysplasias: For infigratinib, we aim to provide a daily oral treatment option with deeper efficacy by targeting both the MAPK pathway and STAT1. Market research shows an oral treatment with similar efficacy could capture about 60% of the market. Q: What would be considered a meaningful win in the upcoming Phase 3 CALIBRATE trial for encaleret? A: Ananth Sridhar, COO, Cardiorenal: A successful study would be a home run for the ADH1 community. The available conventional therapy offers meager benefits, so achieving normalization of both blood and urine calcium would be a significant step forward. In our Phase 2 cohort, 69% of participants achieved normalization on encaleret, compared to 0% on standard care. Q: How do you plan to leverage the data to convince payers and doctors to use Attruby more in the first-line setting? A: Neil Kumar, CEO: We are increasing our scientific share of voice through conferences, publications, and real-world evidence studies. The recent data on variant populations, AFib, and serum TTR levels are key differentiators. We are also focusing on the rapidity of response and real-world experience to highlight Attruby's benefits. Q: What are the areas for growth within the Attruby launch, and what is BridgeBio excited about for the remainder of the year? A: Neil Kumar, CEO: We're excited about the continued clinical differentiation and the concept of early impact and efficacy. The prevention study and rapid stabilization of serum TTR levels are key areas of focus. We're also working on improving access and support programs to ensure that anyone who wants Attruby can get it. Q: What is resonating with new prescribers and repeat prescribing dynamics for Attruby? A: Matthew Outten, Chief Commercial Officer: When HCPs see how quickly Attruby works, it reinforces their decision to prescribe it. The efficacy and support programs have made a significant impact. This is important in both community and academic settings, leading to continued growth in prescriber numbers. Q: How does success in ADH1 translate to hypoparathyroidism, and how do you view responder rates compared to existing therapies? A: Ananth Sridhar, COO, Cardiorenal: ADH1 is the most common genetic subset of hypoparathyroidism, so a positive study would de-risk further evaluation in chronic hypoparathyroidism. Rapid and durable benefits on blood and urine calcium, along with safety, are key aspects. In our Sentinel study, 80% of participants normalized blood and urine calcium within 5 days of dosing with encaleret. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
26-07-2025
- Business
- Yahoo
Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. A closeup of a medical technician handling a sample of a biopharmaceutical drug. Citing its growing use as a first-line therapy due to ease of access and better stabilizer data, Truist sees strong traction among tafamidis-progressing patients. With the ATTR-CM market expected to reach $20 billion, Truist views significant upside for Attruby despite ongoing patent litigation from Pfizer. The firm remains optimistic about BridgeBio's IP position and also highlighted near-term growth catalysts from its late-stage pipeline, particularly starting in the second half of 2025. BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases and cancers with clear genetic drivers. It boasts a pipeline of candidate drugs, some in early-stage research and others in advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Globe and Mail
22-07-2025
- Business
- Globe and Mail
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the 'Events & Presentations' page within the Investors section of the BridgeBio website at A replay of the webcast will be available on the BridgeBio website for 30 days following the event. Participants may access the webcast by registering online using the following link, About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn, Twitter, Facebook, and YouTube.
Yahoo
22-07-2025
- Business
- Yahoo
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the 'Events & Presentations' page within the Investors section of the BridgeBio website at A replay of the webcast will be available on the BridgeBio website for 30 days following the event. Participants may access the webcast by registering online using the following link, About BridgeBio Pharma, Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn, Twitter, Facebook, and YouTube. BridgeBio Media Contact:Bubba Murarka, Executive Vice President, Corporate Developmentcontact@ (650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, Senior Vice President, Strategic Financeir@ in to access your portfolio
